Related Experiment Videos
Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy
E Demirtaş1, C Sağ, H Kurşaklioğlu
1Faculty of Medicine, Department of Cardiology, Gülhane Military Medical Academy, Ankara, Turkey.
Insights
Octreotide treatment significantly reduced interventricular septum thickness and subaortic gradient in patients with hypertrophic obstructive cardiomyopathy (HOCM). This suggests octreotide may be a promising new therapy for HOCM.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) is a cardiac condition characterized by left ventricular outflow tract obstruction and increased interventricular septum thickness.
- The exact cause of HOCM remains unknown, necessitating exploration of novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of octreotide, a somatostatin analogue, in treating patients with HOCM.
- To assess the impact of octreotide on echocardiographic parameters and subaortic gradient in HOCM patients.
Main Methods:
- A 6-month subcutaneous administration of octreotide to 15 HOCM patients.
- Echocardiographic examinations were conducted before and after the treatment period.
Main Results:
- Significant decreases were observed in interventricular septum thickness, the ratio of interventricular septum thickness to left ventricular posterior wall thickness, and the subaortic gradient.
- The ratio of mitral valve E to A waves increased significantly, indicating improved diastolic function.
- No significant changes were noted in left ventricular dimensions, ejection fraction, or fractional shortening. No adverse effects were reported.
Conclusions:
- Octreotide demonstrated beneficial effects in HOCM patients, notably reducing interventricular septum thickness and subaortic pressure gradient.
- Octreotide presents a potential new therapeutic approach for managing hypertrophic obstructive cardiomyopathy.
Abstract:
Hypertrophic obstructive cardiomyopathy (HOCM), the cause of which is unknown, is a heart disease characterized by obstruction of the left ventricular outflow tract and an increase in interventricular septum thickness. Octreotide, a synthetic analogue of somatostatin, was administered subcutaneously to 15 patients for 6 months in order to determine its efficacy in HOCM. Echocardiographic examination was performed in each patient before we had initiated treatment and after treatment. Interventricular septum thickness, interventricular septum thickness/left ventricular posterior wall thickness, and subaortic gradient decreased significantly at the end of treatment. The ratio of the mitral valve E to A waves increased significantly. We observed that octreotide treatment caused a significant decrease in interventricular septum thickness and subaortic pressure gradient. Before and after therapy left ventricular enddiastolic diameter, left ventricular endsystolic diameter, ejection fraction and fractional shortening were not changed. No adverse effect was observed during the therapy. According to our results, octreotide has some beneficial effects on HOCM and it seems to be a new therapeutic approach for HOCM.